Investigational drug · Phase 3
ZG005
Not approved by FDA. In 11 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
11
10 still active
All registered trials
16
Any phase or sponsor naming "ZG005"
First trial start
2022
Jun 17, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ZG005", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumor
- Lymphoma
- Non-small Cell Lung Cancer
- Biliary Tract Carcinoma
- Neuroendocrine Carcinomas (NEC)
- Small Cell Lung Cancer
- Neuroendocrine Carcinoma
- Hepatocellular Carcinoma
- Cervical Cancer
- Solid Tumors
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Liver cancer (hepatocellular carcinoma) · Cervical cancer · Oncology · Hematology and blood cancers · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "ZG005" as an intervention, largest first.
- ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced HepatocellularPivotal-lookingRecruiting
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT07813572 · 600 participants (planned) · Start Oct 20, 2026 · Primary completion Sep 2031
Drug: ZG005 for Injection; Bevacizumab ( Avastin) and 2 more · For: Hepatocellular Carcinoma
Sites: Nanjing, China
- ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine CarcinomaPivotal-lookingNot yet recruiting
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT07833839 · 440 participants (planned) · Start Oct 2026 · Primary completion Oct 2031
Drug: ZG005 for Injection; Etoposide Injection and 2 more · For: Neuroendocrine Carcinomas (NEC)
Sites: Zhengzhou, China
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT07038096 · 350 participants (planned) · Start Sep 23, 2025 · Primary completion Sep 2027
Drug: ZG006; ZG005 · For: Small Cell Lung Cancer; Neuroendocrine Carcinoma
Sites: Guanzhou, China
- Study of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid TumorsPivotal-lookingNot yet recruiting
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT07142837 · 153 participants (planned) · Start Sep 2025 · Primary completion Oct 2027
Drug: ZG005; Gecacitinib · For: Advanced Solid Tumor
Sites: Beijing, China
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT06239298 · 130 participants (planned) · Start May 10, 2024 · Primary completion Mar 2026
Drug: ZG005 Powder for Injection; Donafenib Tosilate Tablets · For: Solid Tumor
Sites: Chongqing, China
- A Study of ZG005 in Patients With Advanced Solid TumorsPivotal-lookingCompleted
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT06233292 · 125 participants · Start Jun 17, 2022 · Primary completion Jul 22, 2026
Drug: ZG005 Powder for Injection; ZG005 Powder for Injection · For: Solid Tumors
Sites: Hangzhou, China
- Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical CancerPivotal-lookingRecruiting
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT07080216 · 120 participants (planned) · Start Sep 23, 2025 · Primary completion Aug 2027
Drug: ZG005; Gecacitinib and 1 more · For: Cervical Cancer
Sites: Hangzhou, China
- Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.Status unknown
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT06372626 · 93 participants (planned) · Start May 30, 2024 · Primary completion Jul 2026
Drug: ZG005; Etoposide and 2 more · For: Neuroendocrine Carcinoma
Sites: Beijing, China
- Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular CarcinomaStatus unknown
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT06558227 · 90 participants (planned) · Start Oct 24, 2024 · Primary completion Sep 2026
Drug: ZG005 for Injection; Bevacizumab and 2 more · For: Hepatocellular Carcinoma
Sites: Chengdu, China
Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
NCT06938880 · 60 participants (planned) · Start May 20, 2025 · Primary completion May 2027
Drug: ZGGS18 for Injection; ZG005 for Injection · For: Advanced Solid Tumor
Sites: Guangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Solid Tumor
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- TQB2102Phase 311 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Breast Cancer, HER2-positive Breast Cancer, Gynecological Tumors
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
- UtidelonePhase 38 trials
Beijing Biostar Pharmaceuticals Co., Ltd. · Ovarian Cancer, HER2-negative Breast Cancer Patients With Brain Metastases, Gastric or Gastroesophageal Junction Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.